At a glance

ClinicalIndex Comparison Record

Phase 4Completed· 118 enrolled

Drug / intervention

Rivastigmine Patchdrug

Likely dose

Rivastigmine Patch 9.0 mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02703636

NCT02703636Phase 4Completed

Compare CT.gov

A 24-week, Open-label, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Rivastigmine Patch With 1-step Titration in Patients With Mild to Moderate Alzheimer's Disease (MMSE 10 - 23) Switched Directly From Holinesterase Inhibitors (Donepezil, Galantamine)

Novartis Pharmaceuticals·interventional·Posted Mar 9, 2016·Updated Sep 12, 2019

In Brief

A Phase 4 clinical trial evaluating Rivastigmine Patch for Mild to Moderate Alzheimer's Disease. Completed, enrolled 118 participants across 19 sites.

Detailed Summary

To evaluate the efficacy of rivastigmine patch with 1-step titration on cognitive function measured as change from baseline to week 24 in the total score of Mini-Mental State Examination (MMSE) in mild to moderate Alzheimer's disease (AD) patients who failed to benefit from other cholinesterase inhibitors (ChEIs).

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsMild to Moderate Alzheimer's Disease

CountriesJapan

Collaborators--

Timeline

Phase 4CompletedFinished

20162017201820192020202120222023202420252026

First PostedMar 2016

Enrollment StartMay 2016

Primary CompletionMay 2018

TodayJul 2026

First PostedMar 9, 2016

Enrollment StartMay 9, 2016

Primary CompletionMay 7, 2018

TodayJul 2, 2026

Enrollment to primary: 2.0 yearsPosted 10.3 years ago

Interventions

Rivastigmine Patchdrug

Alzheimer's disease patient who is applicable to 1 step titration method (initial loading dose is a rivastigmine patch 9.0 mg/day and will be up-titrated after 4 weeks to reach the maintenance dose of 18 mg/day). Rivastigmine patch is a marketed drug, therefore the dose, dose regimen and titration scheme are in accordance with product label.